poisar

Stocks · News reference

Viatris Subsidiary Peach Purchaser Sub Commences Tender Offer To Acquire Pacira Biosciences For $36.50/Shr

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

PCRXVTRS
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  3. Na

    Here's What Key Metrics Tell Us About Viatris (VTRS) Q3 Earnings

    Viatris reported Q3 2026 revenue of $3.75 billion, down 0.3% year-over-year and slightly missing consensus estimates by 0.76%. However, the company delivered a strong EPS beat of 10.94%, reporting $0.71 versus the expected $0.64. Regional performance was mixed, with Greater China showing strong growth of 14.2%, while Emerging Markets Generics declined sharply by 36.5%. The stock has outperformed the broader market with a 9.9% return over the past month and currently holds a Zacks Rank #3 (Hold) rating.

    VTRS
  5. Earnings Transcripts

    Viatris Q3 2026 Earnings Call Transcript

    Viatris (NASDAQ:VTRS) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. For

    VTRS
  6. SEC EDGAR

    8-K filing — Viatris Inc (VTRS)

    Filed: 2026-11-05 AccNo: 0001792044-26-000053 Size: 872 KB Item 2.02: Results of Operations and Financial Condition Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

    VTRS